Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.

Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC.

Open source

DOI: 10.1200/jco.23.01017
Published: 2024-01-22
Container: J Clin Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.23.01017,
  title = {Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.},
  author = {Mok T and  Nakagawa K and  Park K and  Ohe Y and  Girard N and  Kim HR and  Wu YL and  Gainor J and  Lee SH and  Chiu CH and  Kim SW and  Yang CT and  Wu CL and  Wu L and  Lin MC and  Samol J and  Ichikado K and  Wang M and  Zhang X and  Sylvester J and  Li S and  Forslund A and  Yang JC.},
  year = {2024},
  journal = {J Clin Oncol},
  doi = {10.1200/jco.23.01017},
  url = {https://doi.org/10.1200/jco.23.01017}
}

RIS

TY  - JOUR
TI  - Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
AU  - Mok T
AU  -  Nakagawa K
AU  -  Park K
AU  -  Ohe Y
AU  -  Girard N
AU  -  Kim HR
AU  -  Wu YL
AU  -  Gainor J
AU  -  Lee SH
AU  -  Chiu CH
AU  -  Kim SW
AU  -  Yang CT
AU  -  Wu CL
AU  -  Wu L
AU  -  Lin MC
AU  -  Samol J
AU  -  Ichikado K
AU  -  Wang M
AU  -  Zhang X
AU  -  Sylvester J
AU  -  Li S
AU  -  Forslund A
AU  -  Yang JC.
PY  - 2024
JO  - J Clin Oncol
DO  - 10.1200/jco.23.01017
UR  - https://doi.org/10.1200/jco.23.01017
ER  -

APA

T, M., K, N., K, P., Y, O., N, G., HR, K., YL, W., J, G., SH, L., CH, C., SW, K., CT, Y., CL, W., L, W., MC, L., J, S., K, I., M, W., X, Z., J, S., S, L., A, F., & JC., Y. (2024). Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.. J Clin Oncol. https://doi.org/10.1200/jco.23.01017

Source records

europe-pmc · retrieved 2026-09-26T14:47:17.733Z